International Journal of Hematology

, Volume 90, Issue 1, pp 58–63

Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001

  • Roberto H. Nussenzveig
  • Jorge Cortes
  • Matjaz Sever
  • Alfonso Quintás-Cardama
  • Pat Ault
  • Taghi Manshouri
  • Carlos Bueso-Ramos
  • Josef T. Prchal
  • Hagop Kantarjian
  • Srdan Verstovsek
Original Article

Abstract

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by excessive production of red blood cells. Patients with PV are at a risk of thrombosis, bleeding, and transformation to myelofibrosis or acute myeloid leukemia. Therapy for PV is based on the use of phlebotomy, aspirin, and in high-risk patients, cytoreductive agents such as hydroxyurea. Anecdotal evidence suggests that imatinib mesylate, a selective tyrosine kinase inhibitor of ABL1, ARG, PDGFR, and KIT kinases has activity in PV. We conducted an open-label phase II clinical trial of imatinib at the standard dose of 400 mg daily in 24 patients with PV. The median duration of imatinib therapy was 5.1 months (range 0.2–86.4). Overall, 4 (17%) patients responded: one had a complete and three partial hematological response. The median time to response was 17.5 months (range 6–28), and the median duration of response was 17 months (range 9–68). No significant changes in JAK2V617F mutation burden were noted during imatinib therapy when compared with pretreatment values (P = 0.46). Therapy with imatinib was generally well tolerated. Our data indicate that imatinib has minimal clinical activity in PV.

Keywords

Imatinib mesylate Polycythemia vera JAK2 mutation 

References

  1. 1.
    Prchal JF, Prchal JT. Molecular basis for polycythemia. Curr Opin Hematol. 1999;6(2):100–9. doi:10.1097/00062752-199903000-00008.PubMedCrossRefGoogle Scholar
  2. 2.
    Prchal JF, Axelrad AA. Letter: bone-marrow responses in polycythemia vera. N Engl J Med. 1974;290(24):1382.PubMedGoogle Scholar
  3. 3.
    Druker BJ, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038–42. doi:10.1056/NEJM200104053441402.PubMedCrossRefGoogle Scholar
  4. 4.
    Cortes J, Kantarjian H. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. Cancer. 2004;100(10):2064–78. doi:10.1002/cncr.20211.PubMedCrossRefGoogle Scholar
  5. 5.
    Oehler L, et al. Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro. Blood. 2003;102(6):2240–2. doi:10.1182/blood-2003-03-0676.PubMedCrossRefGoogle Scholar
  6. 6.
    Gaikwad A, et al. Imatinib effect on growth and signal transduction in polycythemia vera. Exp Hematol. 2007;35(6):931–8. doi:10.1016/j.exphem.2007.03.012.PubMedCrossRefGoogle Scholar
  7. 7.
    Jones CM, Dickinson TM. Polycythemia vera responds to imatinib mesylate. Am J Med Sci. 2003;325(3):149–52. doi:10.1097/00000441-200303000-00007.PubMedCrossRefGoogle Scholar
  8. 8.
    Silver RT. Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera. Leukemia. 2003;17(6):1186–7. doi:10.1038/sj.leu.2402938.PubMedCrossRefGoogle Scholar
  9. 9.
    Silver RT. Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate. Curr Hematol Rep. 2005;4(3):235–7.PubMedGoogle Scholar
  10. 10.
    Spivak JL, Silver RT. Imatinib mesylate in polycythemia vera. Blood. 2004;103(8):3241. doi:10.1182/blood-2003-12-4248. author reply 3241–3242.PubMedCrossRefGoogle Scholar
  11. 11.
    Baxter EJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–61.PubMedGoogle Scholar
  12. 12.
    James C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–8. doi:10.1038/nature03546.PubMedCrossRefGoogle Scholar
  13. 13.
    Kralovics R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–90. doi:10.1056/NEJMoa051113.PubMedCrossRefGoogle Scholar
  14. 14.
    Levine RL, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97. doi:10.1016/j.ccr.2005.03.023.PubMedCrossRefGoogle Scholar
  15. 15.
    Lacout C, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108(5):1652–60.Google Scholar
  16. 16.
    Jones AV, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6):2162–8. doi:10.1182/blood-2005-03-1320.PubMedCrossRefGoogle Scholar
  17. 17.
    Verstovsek S, et al. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia. 2006;20(11):2067. doi:10.1038/sj.leu.2404379.PubMedCrossRefGoogle Scholar
  18. 18.
    Nussenzweig RH, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35(1):32–8.Google Scholar
  19. 19.
    Druker BJ, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561–6. doi:10.1038/nm0596-561.PubMedCrossRefGoogle Scholar
  20. 20.
    Zhao R, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280(24):22788–92. doi:10.1074/jbc.C500138200.PubMedCrossRefGoogle Scholar
  21. 21.
    Weiler SR, et al. JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. Blood. 1996;87(9):3688–93.PubMedGoogle Scholar
  22. 22.
    Fontalba A, et al. Identification of c-Kit gene mutations in patients with polycythemia vera. Leuk Res. 2006;30(10):1325–6. doi:10.1016/j.leukres.2005.12.020.PubMedCrossRefGoogle Scholar
  23. 23.
    Zaleskas VM, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One. 2006;1:e18. doi:10.1371/journal.pone.0000018.PubMedCrossRefGoogle Scholar
  24. 24.
    Silver R, Fruchtman S, Feldman E, et al. Imatinib mesylate (Gleevec) is effective in the treatment of polycythemia vera: a multi-institutional clinical trial. Blood. 2004;104(11):189a.Google Scholar
  25. 25.
    Jones CM, Dickinson TM, Salvado A. Phase II open label trial of imatinib in polycythemia rubra vera. Int J Hematol. 2008;88(5):489–94. doi:10.1007/s12185-008-0193-1.PubMedCrossRefGoogle Scholar
  26. 26.
    Jones AV, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood. 2006;107(8):3339–41. doi:10.1182/blood-2005-09-3917.PubMedCrossRefGoogle Scholar
  27. 27.
    Quintas-Cardama AC, J, Kantarjian H. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma. 2008;8(Suppl. 3):S82–8. doi:10.3816/CLM.2008.s.003.

Copyright information

© The Japanese Society of Hematology 2009

Authors and Affiliations

  • Roberto H. Nussenzveig
    • 1
    • 4
  • Jorge Cortes
    • 1
  • Matjaz Sever
    • 1
  • Alfonso Quintás-Cardama
    • 1
  • Pat Ault
    • 1
  • Taghi Manshouri
    • 1
  • Carlos Bueso-Ramos
    • 2
  • Josef T. Prchal
    • 3
  • Hagop Kantarjian
    • 1
  • Srdan Verstovsek
    • 1
  1. 1.Department of LeukemiaM.D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of HematopathologyUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA
  3. 3.Division of Hematology, School of MedicineUniversity of UtahSalt Lake CityUSA
  4. 4.ARUP LaboratoriesSalt Lake CityUSA

Personalised recommendations